Becton, Dickinson and Company (NYSE:BDX) Price Target Lowered to $232.00 at Citigroup

Becton, Dickinson and Company (NYSE:BDX) had its price objective decreased by Citigroup from $233.00 to $232.00 in a research note released on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the medical instruments supplier’s stock.

BDX has been the topic of a number of other research reports. Piper Sandler reaffirmed a “neutral” rating and set a $170.00 price target (down previously from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday. Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Barclays began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday. They issued an “overweight” rating and a $202.00 price target on the stock. Royal Bank Of Canada lowered their price objective on shares of Becton, Dickinson and Company from $210.00 to $172.00 and set a “sector perform” rating for the company in a research report on Monday. Finally, Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $196.00.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $171.55 on Tuesday. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $235.34. The stock has a market capitalization of $48.88 billion, a P/E ratio of 27.99, a P/E/G ratio of 2.72 and a beta of 0.25. The business has a 50-day moving average price of $199.76 and a two-hundred day moving average price of $192.43.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 2,463 shares of company stock worth $501,530. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Activest Wealth Management boosted its holdings in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the third quarter valued at $25,000. SOA Wealth Advisors LLC. grew its position in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares during the period. Steph & Co. increased its stake in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the last quarter. Finally, Bell Investment Advisors Inc raised its holdings in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 results beat consensus — adjusted EPS $2.91 vs. $2.81 expected and revenue $5.25B vs. $5.15B, showing organic revenue stability and margin improvement that would normally support the stock. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Company announced up to $1.6B in cash tender offers to repurchase certain outstanding debt — a signal of active balance‑sheet management that can reduce leverage and interest burden. Tender Offers for Outstanding Debt Securities
• Positive Sentiment: Barclays initiated coverage with an Overweight and $202 PT — a notable constructive analyst call amid mixed revisions. Barclays Overweight Initiation
• Neutral Sentiment: Spin-off/combination with Waters completed — a structural change that reduces BD’s scale and alters its earnings base; investors are re‑valuing the “New BD” through guidance and cash deployment plans. Spin-off/Combination Announcement
• Neutral Sentiment: Insiders placed bullish option bets (reported) — a small positive signal of insider confidence but not large enough to move fundamentals alone. Insider Option Activity
• Negative Sentiment: Company cut FY26 adjusted EPS guidance to $12.35–$12.65, well below consensus (~$14.8) — the guidance reset (reflecting the divestiture) is the primary negative driver pushing the stock lower as investors adjust earnings models. Profit Forecast Cut
• Negative Sentiment: Multiple broker price‑target cuts and rating adjustments (JPMorgan, Wells Fargo, Jefferies, RBC and others) compress sentiment — several firms lowered PTs or shifted to neutral/equal‑weight, increasing selling pressure. Analyst Price Target Moves
• Negative Sentiment: Company flagged a reduced profit outlook tied to the sale/combination of its biosciences & diagnostics unit — the near‑term EPS hit and uncertainty around cash deployment timing weigh on valuation. Sale‑Related Profit Outlook

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.